A61K 31/513
Having oxo groups directly attached to the heterocyclic ring
Official title: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K31/513 (Having oxo groups directly attached to the heterocyclic ring) appears on 2,350 US grants and 4,794 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,350
- Published applications
- 4,794
- Assignees
- 1,892
- Inventors
- 9,390
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 2 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 2 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 5 | 0 |
| 1996 | 7 | 0 |
| 1997 | 7 | 0 |
| 1998 | 15 | 0 |
| 1999 | 25 | 0 |
| 2000 | 12 | 0 |
| 2001 | 27 | 13 |
| 2002 | 18 | 47 |
| 2003 | 26 | 81 |
| 2004 | 22 | 75 |
| 2005 | 26 | 100 |
| 2006 | 24 | 103 |
| 2007 | 23 | 105 |
| 2008 | 25 | 90 |
| 2009 | 21 | 103 |
| 2010 | 51 | 126 |
| 2011 | 38 | 134 |
| 2012 | 79 | 137 |
| 2013 | 89 | 193 |
| 2014 | 122 | 286 |
| 2015 | 134 | 269 |
| 2016 | 164 | 262 |
| 2017 | 169 | 300 |
| 2018 | 165 | 247 |
| 2019 | 161 | 243 |
| 2020 | 165 | 241 |
| 2021 | 128 | 291 |
| 2022 | 127 | 286 |
| 2023 | 112 | 304 |
| 2024 | 120 | 262 |
| 2025 | 122 | 249 |
| 2026 | 105 | 247 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Nanostructure or microstructure and method for producing same6 Oct 2026US 12,751,923 B2The University of Tokyo
- Method of predicting therapeutic response and prognosis of metastatic breast cancer to chemotherapeutic agents, and treating metastatic breast cancer6 Oct 2026US 12,753,447 B2Samsung Life Public Welfare Foundation
- Imidazole-based synthetic lipidoids for in vivo mRNA delivery into immune cells29 Sep 2026US 12,747,214 B2Trustees of Tufts College
- Use of phthalide compounds in treatment of meningioma22 Sep 2026US 12,740,964 B2Everfront Biotech Inc.
- Small molecule liver X receptor modulators and uses thereof22 Sep 2026US 12,740,985 B2University of Houston System
- Methods of preventing post-traumatic osteoarthritis using metformin8 Oct 2026US 2026/0306428 A1
- Inverse agonists of rar related orphan receptors (rors)8 Oct 2026US 2026/0306484 A111949098 CANADA INC. (NUREDCO) c/o Jean I. TCHERVENKOV
- Use of milvexian in the treatment and prevention of thrombotic conditions in patients with atrial fibrilation8 Oct 2026US 2026/0306492 A1Bristol-Myers Squibb Company
- A combination therapy for cancer treatment8 Oct 2026US 2026/0306633 A1Purdue Research Foundation
- Estrogen-receptor modulator and use thereof8 Oct 2026US 2026/0308139 A1Jiangsu Vcare PharmaTech Co., Ltd.
Most cited
By later US patents
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Supplemented and unsupplemented tissue sealants, methods of their production and use441US 6,197,325 B1American National Red Cross · 2001
- Abuse-proofed dosage form249US 8,114,383 B2Gruenenthal GmbH · 2012
- Abuse-proofed dosage form205US 8,309,060 B2GrüNenthal GmbH · 2012
- Method of preparing a tissue sealant-treated biomedical material177US 6,559,119 B1American National Red Cross · 2003